{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:24:15Z","timestamp":1778768655574,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01-CA201092"],"award-info":[{"award-number":["R01-CA201092"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01-CA201092"],"award-info":[{"award-number":["R01-CA201092"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01-CA201092"],"award-info":[{"award-number":["R01-CA201092"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01-CA201092"],"award-info":[{"award-number":["R01-CA201092"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-025-00604-z","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:51:46Z","timestamp":1763416306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["WEE1 inhibition delays resistance to CDK4\/6 inhibitor and antiestrogen treatment in ER+\u2009MCF7 cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Wei","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M.","family":"Demas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Kraikivski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha N.","family":"Shajahan-Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"604_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"604_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288 (2019).","journal-title":"JAMA"},{"key":"604_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.bjc.6605845","volume":"103","author":"YH Chia","year":"2010","unstructured":"Chia, Y. H., Ellis, M. J. & Ma, C. X. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br. J. Cancer 103, 759\u2013764 (2010).","journal-title":"Br. J. Cancer"},{"key":"604_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"604_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell 37, 496\u2013513 (2020).","journal-title":"Cancer Cell"},{"key":"604_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi, S. & De Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39\u201356 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"604_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde, R. et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat. Commun. 11, 2393 (2020).","journal-title":"Nat. Commun."},{"key":"604_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"604_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00578-3","volume":"9","author":"J Ma","year":"2023","unstructured":"Ma, J., Chan, J. J., Toh, C. H. & Yap, Y.-S. Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. npj Breast Cancer 9, 74 (2023).","journal-title":"npj Breast Cancer"},{"key":"604_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrc2713","volume":"9","author":"EA Musgrove","year":"2009","unstructured":"Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631\u2013643 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"604_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mc.23646","volume":"63","author":"ER Scheidemann","year":"2024","unstructured":"Scheidemann, E. R. et al. Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells. Mol. Carcinog. 63, 209\u2013223 (2024).","journal-title":"Mol. Carcinog."},{"key":"604_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","volume":"4","author":"R Salgia","year":"2018","unstructured":"Salgia, R. & Kulkarni, P. The genetic\/non-genetic duality of drug \u2018resistance\u2019 in cancer. Trends Cancer 4, 110\u2013118 (2018).","journal-title":"Trends Cancer"},{"key":"604_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"604_CR14","doi-asserted-by":"publisher","first-page":"111716","DOI":"10.1016\/j.jtbi.2023.111716","volume":"579","author":"MM Fischer","year":"2024","unstructured":"Fischer, M. M. & Bl\u00fcthgen, N. On minimising tumoural growth under treatment resistance. J. Theor. Biol. 579, 111716 (2024).","journal-title":"J. Theor. Biol."},{"key":"604_CR15","doi-asserted-by":"crossref","unstructured":"He, W., McCoy, M. D., Riggins, R. B., Beckman, R. A. & Yeang, C.-H. Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms. npj Syst. Biol. Appl. 11, 70 (2025).","DOI":"10.1038\/s41540-025-00547-5"},{"key":"604_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679\u2013692 (2012).","journal-title":"Nat. Biotechnol."},{"key":"604_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks, P. et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603, 166\u2013173 (2022).","journal-title":"Nature"},{"key":"604_CR18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1158\/2159-8290.CD-20-1187","volume":"11","author":"J Settleman","year":"2021","unstructured":"Settleman, J., Neto, J. M. F. & Bernards, R. Thinking differently about cancer treatment regimens. Cancer Discov. 11, 1016\u20131023 (2021).","journal-title":"Cancer Discov."},{"key":"604_CR19","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-23-0112","volume":"29","author":"GN Schwartz","year":"2023","unstructured":"Schwartz, G. N. et al. Alternating 17\u03b2-Estradiol and aromatase inhibitor therapies is efficacious in postmenopausal women with advanced endocrine-resistant ER+ breast cancer. Clin. Cancer Res. 29, 2767\u20132773 (2023).","journal-title":"Clin. Cancer Res."},{"key":"604_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"604_CR21","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-17-0520","volume":"23","author":"JJJ Geenen","year":"2017","unstructured":"Geenen, J. J. J. & Schellens, J. H. M. Molecular pathways: targeting the protein kinase Wee1 in cancer. Clin. Cancer Res. 23, 4540\u20134544 (2017).","journal-title":"Clin. Cancer Res."},{"key":"604_CR22","doi-asserted-by":"publisher","first-page":"681530","DOI":"10.3389\/fonc.2021.681530","volume":"11","author":"Y Fallah","year":"2021","unstructured":"Fallah, Y., Demas, D. M., Jin, L., He, W. & Shajahan-Haq, A. N. Targeting WEE1 inhibits growth of breast cancer cells that are resistant to endocrine therapy and CDK4\/6 inhibitors. Front. Oncol. 11, 681530 (2021).","journal-title":"Front. Oncol."},{"key":"604_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","volume":"2","author":"M Aarts","year":"2012","unstructured":"Aarts, M. et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2, 524\u2013539 (2012).","journal-title":"Cancer Discov."},{"key":"604_CR24","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.18632\/oncotarget.14089","volume":"8","author":"S Hauge","year":"2017","unstructured":"Hauge, S. et al. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Oncotarget 8, 10966\u201310979 (2017).","journal-title":"Oncotarget"},{"key":"604_CR25","doi-asserted-by":"publisher","first-page":"111694","DOI":"10.1016\/j.mrfmmm.2020.111694","volume":"819\u2013820","author":"CR Elb\u00e6k","year":"2020","unstructured":"Elb\u00e6k, C. R., Petrosius, V. & S\u00f8rensen, C. S. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat. Res. Fundam. Mol. Mech. Mutagen 819\u2013820, 111694 (2020).","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen"},{"key":"604_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110261","volume":"38","author":"CR Elb\u00e6k","year":"2022","unstructured":"Elb\u00e6k, C. R. et al. WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity. Cell Rep. 38, 110261 (2022).","journal-title":"Cell Rep."},{"key":"604_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1083\/jcb.200905059","volume":"188","author":"H Beck","year":"2010","unstructured":"Beck, H. et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J. Cell Biol. 188, 629\u2013638 (2010).","journal-title":"J. Cell Biol."},{"key":"604_CR28","doi-asserted-by":"publisher","first-page":"23891","DOI":"10.1073\/pnas.1915108116","volume":"116","author":"TN Moiseeva","year":"2019","unstructured":"Moiseeva, T. N., Qian, C., Sugitani, N., Osmanbeyoglu, H. U. & Bakkenist, C. J. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- And S-phase cells. Proc. Natl. Acad. Sci. USA 116, 23891\u201323893 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"604_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/nar\/gkr697","volume":"40","author":"CS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen, C. S. & Sylju\u00e5sen, R. G. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 40, 477\u2013486 (2012).","journal-title":"Nucleic Acids Res."},{"key":"604_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 155, 1088 (2013).","journal-title":"Cell"},{"key":"604_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard, H., Garc\u00eda-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276\u2013289 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"604_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. Mech. Dis. 10, 425\u2013448 (2015).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"604_CR33","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-18-0618","volume":"78","author":"F B\u00e9langer","year":"2018","unstructured":"B\u00e9langer, F. et al. Replication Protein A availability during DNA replication stress is a major determinant of Cisplatin resistance in ovarian cancer cells. Cancer Res. 78, 5561\u20135573 (2018).","journal-title":"Cancer Res."},{"key":"604_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrd4553","volume":"14","author":"M Dobbelstein","year":"2015","unstructured":"Dobbelstein, M. & S\u00f8rensen, C. S. Exploiting replicative stress to treat cancer. Nat. Rev. Drug Discov. 14, 405\u2013423 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"604_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41568-022-00518-6","volume":"23","author":"E Cybulla","year":"2023","unstructured":"Cybulla, E. & Vindigni, A. Leveraging the replication stress response to optimize cancer therapy. Nat. Rev. Cancer 23, 6\u201324 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"604_CR36","doi-asserted-by":"publisher","first-page":"774845","DOI":"10.3389\/fcell.2021.774845","volume":"9","author":"R Fagundes","year":"2021","unstructured":"Fagundes, R. & Teixeira, L. K. Cyclin E\/CDK2: DNA replication, replication stress and genomic instability. Front. Cell Dev. Biol. 9, 774845 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"604_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.cell.2022.12.036","volume":"186","author":"J Zeng","year":"2023","unstructured":"Zeng, J., Hills, S. A., Ozono, E. & Diffley, J. F. X. Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication. Cell 186, 528\u2013542.e14 (2023).","journal-title":"Cell"},{"key":"604_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00270-2","volume":"9","author":"YP Kok","year":"2020","unstructured":"Kok, Y. P. et al. Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis 9, 88 (2020).","journal-title":"Oncogenesis"},{"key":"604_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00181-w","volume":"6","author":"S Guerrero Llobet","year":"2020","unstructured":"Guerrero Llobet, S. et al. Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer. npj Breast Cancer 6, 40 (2020).","journal-title":"npj Breast Cancer"},{"key":"604_CR40","doi-asserted-by":"publisher","unstructured":"Gini, B. et al. CDK4 and CDK6 upregulation promotes DNA replication stress, genomic instability and resistance to EGFR targeted therapy in lung cancer. Preprint at https:\/\/doi.org\/10.1101\/2024.03.12.584638 (2024).","DOI":"10.1101\/2024.03.12.584638"},{"key":"604_CR41","doi-asserted-by":"publisher","first-page":"15160","DOI":"10.1073\/pnas.1505283112","volume":"112","author":"AM Heijink","year":"2015","unstructured":"Heijink, A. M. et al. A haploid genetic screen identifies the G1\/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity. Proc. Natl. Acad. Sci. USA 112, 15160\u201315165 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"604_CR42","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76, 2301\u20132313 (2016).","journal-title":"Cancer Res."},{"key":"604_CR43","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: Neoadjuvant Palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 Estrogen Receptor\u2013Positive Breast Cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res."},{"key":"604_CR44","doi-asserted-by":"crossref","unstructured":"Turner, N. C. et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor \u2013 positive metastatic breast cancer. J. Clin. Oncol. 37, 1\u201311 (2019).","DOI":"10.1200\/JCO.18.00925"},{"key":"604_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0092-4","volume":"4","author":"C Guarducci","year":"2018","unstructured":"Guarducci, C. et al. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. npj Breast Cancer 4, 38 (2018).","journal-title":"npj Breast Cancer"},{"key":"604_CR46","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-15-1984","volume":"22","author":"CL Alves","year":"2016","unstructured":"Alves, C. L. et al. High CDK6 protects cells from Fulvestrant-Mediated apoptosis and is a predictor of resistance to Fulvestrant in estrogen receptor\u2013positive metastatic breast cancer. Clin. Cancer Res. 22, 5514\u20135526 (2016).","journal-title":"Clin. Cancer Res."},{"key":"604_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01402-1","volume":"23","author":"K Kaminska","year":"2021","unstructured":"Kaminska, K. et al. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Res. 23, 26 (2021).","journal-title":"Breast Cancer Res."},{"key":"604_CR48","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/bjc.2013.583","volume":"109","author":"B Giessrigl","year":"2013","unstructured":"Giessrigl, B. et al. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI\/SNF chromatin remodelling complex. Br. J. Cancer 109, 2751\u20132762 (2013).","journal-title":"Br. J. Cancer"},{"key":"604_CR49","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41388-020-1284-6","volume":"39","author":"S Pancholi","year":"2020","unstructured":"Pancholi, S. et al. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene 39, 4781\u20134797 (2020).","journal-title":"Oncogene"},{"key":"604_CR50","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. Clin. Cancer Res. 24, 6594\u20136610 (2018).","journal-title":"Clin. Cancer Res."},{"key":"604_CR51","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu, S. et al. Multicenter Phase II Trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J. Clin. Oncol. 41, 1725\u20131734 (2023).","journal-title":"J. Clin. Oncol."},{"key":"604_CR52","doi-asserted-by":"publisher","first-page":"TPS5612","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5612","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu, J. F. et al. ADAGIO: a phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. J. Clin. Oncol. 39, TPS5612\u2013TPS5612 (2021).","journal-title":"J. Clin. Oncol."},{"key":"604_CR53","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","volume":"27","author":"N Takebe","year":"2021","unstructured":"Takebe, N. et al. Safety, antitumor activity, and biomarker analysis in a Phase I trial of the once-daily Wee1 inhibitor Adavosertib (AZD1775) in patients with advanced solid tumors. Clin. Cancer Res. 27, 3834\u20133844 (2021).","journal-title":"Clin. Cancer Res."},{"key":"604_CR54","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","volume":"35","author":"Y Fang","year":"2019","unstructured":"Fang, Y. et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell 35, 851\u2013867.e7 (2019).","journal-title":"Cancer Cell"},{"key":"604_CR55","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"key":"604_CR56","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/0008-5472.CAN-16-2871","volume":"77","author":"S Chakrabarti","year":"2017","unstructured":"Chakrabarti, S. & Michor, F. Pharmacokinetics and drug-interactions determine optimum combination strategies in computational models of cancer evolution. Cancer Res. 77, 3908\u20133921 (2017).","journal-title":"Cancer Res."},{"key":"604_CR57","doi-asserted-by":"publisher","first-page":"20200339","DOI":"10.1098\/rsif.2020.0339","volume":"17","author":"W He","year":"2020","unstructured":"He, W., Demas, D. M., Conde, I. P., Shajahan-Haq, A. N. & Baumann, W. T. Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4\/6 inhibition. J. R. Soc. Interface 17, 20200339 (2020).","journal-title":"J. R. Soc. Interface"},{"key":"604_CR58","doi-asserted-by":"publisher","first-page":"106714","DOI":"10.1016\/j.isci.2023.106714","volume":"26","author":"W He","year":"2023","unstructured":"He, W., Demas, D. M., Shajahan-Haq, A. N. & Baumann, W. T. Modeling breast cancer proliferation, drug synergies, and alternating therapies. iScience 26, 106714 (2023).","journal-title":"iScience"},{"key":"604_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298788","volume":"19","author":"K Taoma","year":"2024","unstructured":"Taoma, K., Ruengjitchatchawalya, M., Liangruksa, M. & Laomettachit, T. Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy. PLoS ONE 19, e0298788 (2024).","journal-title":"PLoS ONE"},{"key":"604_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48305-z","volume":"14","author":"O Nave","year":"2024","unstructured":"Nave, O., Shor, Y., Bar, R., Segal, E. E. & Sigron, M. A new treatment for breast cancer using a combination of two drugs: AZD9496 and palbociclib. Sci. Rep. 14, 1307 (2024).","journal-title":"Sci. Rep."},{"key":"604_CR61","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1158\/0008-5472.CAN-21-1208","volume":"81","author":"J G\u00f3mez Tejeda Za\u00f1udo","year":"2021","unstructured":"G\u00f3mez Tejeda Za\u00f1udo, J. et al. Cell line\u2013specific network models of ER+ Breast cancer identify potential PI3K\u03b1 inhibitor resistance mechanisms and drug combinations. Cancer Res. 81, 4603\u20134617 (2021).","journal-title":"Cancer Res."},{"key":"604_CR62","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1158\/2767-9764.CRC-23-0257","volume":"3","author":"Y-C Cheng","year":"2023","unstructured":"Cheng, Y.-C. et al. Mathematical modeling identifies optimum Palbociclib-fulvestrant dose administration schedules for the treatment of patients with estrogen receptor\u2013positive breast cancer. Cancer Res. Commun. 3, 2331\u20132344 (2023).","journal-title":"Cancer Res. Commun."},{"key":"604_CR63","doi-asserted-by":"crossref","unstructured":"He, W., Shajahan-Haq, A. N. & Baumann, W. T. Mathematically modeling the effect of endocrine and Cdk4\/6 inhibitor therapies on breast cancer cells. In Computational Modeling of Signaling Networks (ed. Nguyen, L. K.) (Springer, 2023).","DOI":"10.1007\/978-1-0716-3008-2_16"},{"key":"604_CR64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","volume":"149","author":"MJ Lee","year":"2012","unstructured":"Lee, M. J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780\u2013794 (2012).","journal-title":"Cell"},{"key":"604_CR65","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/0008-5472.CAN-19-1961","volume":"79","author":"CW Lewis","year":"2019","unstructured":"Lewis, C. W. et al. Upregulation of Myt1 promotes acquired resistance of cancer cells to Wee1 inhibition. Cancer Res. 79, 5971\u20135985 (2019).","journal-title":"Cancer Res."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00604-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:04:28Z","timestamp":1763420668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00604-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1038\/s41540-025-00604-z","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}